

## The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in *CXCR4*<sup>Wild-type</sup> and *CXCR4*<sup>WHIM</sup> mutated Waldenstrom macroglobulinaemia cells

Whole genome sequencing has revealed *MYD88*<sup>L265P</sup> and *CXCR4*<sup>WHIM</sup> somatic mutations in Waldenstrom's Macroglobulinemia (WM) (Treon *et al*, 2012; Hunter *et al*, 2014). *MYD88*<sup>L265P</sup> supports WM cell survival through divergent pathways including Bruton Tyrosine Kinase (BTK) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3KCD, also termed PI3K $\delta$ ) (Yang *et al*, 2013a,b). Ibrutinib targets BTK, while idelalisib targets PI3KCD. Ibrutinib and idelalisib are active in previously treated WM patients, with overall response rates of 87% and 70%, respectively (Treon *et al*, 2013; Gopal *et al*, 2014). Most responses are partial and no complete responses have been observed.

*CXCR4*<sup>WHIM</sup> mutations confer *in vitro* ibrutinib and idelalisib resistance (Cao *et al*, 2014; Roccaro *et al*, 2013) and *CXCR4*<sup>WHIM</sup>-mutated WM patients have lower overall and major responses to ibrutinib (Treon *et al*, 2013). AKT1 and MAPK1 are hyper-activated in *CXCR4*<sup>WHIM</sup>-engineered WM cells following CXCL12 stimulation, and AKT1 is constitutively activated in WM cells from *CXCR4*<sup>WHIM</sup> patients on ibrutinib (Cao *et al*, 2014). The hyper-activation of AKT1 and MAPK1 may contribute to ibrutinib resistance in *CXCR4*<sup>WHIM</sup>-mutated WM patients (Cao *et al*, 2014).

BCL2 is an anti-apoptotic protein that confers resistance to many anti-neoplastic agents used in B-cell malignancies. *BCL2* is overexpressed in primary WM cells (Chng *et al*, 2006). ABT-199 is a highly selective BCL2 antagonist that is clinically active in B-cell malignancies, with major responses observed in 3 of 4 previously treated WM patients (Davids *et al*, 2014). These findings suggest that *BCL2* contributes to WM cell survival.

We therefore investigated whether BCL2 also protects against ibrutinib- and idelalisib-related apoptosis in *CXCR4*<sup>WT</sup> and *CXCR4*<sup>WHIM</sup> WM cells. Written consent was obtained for use of patient samples per our Institutional Review Board. Development of *CXCR4*<sup>WT</sup> and *CXCR4*<sup>S338X</sup> BCWM.1 and MWCL-1 cells was previously reported (Cao *et al*, 2014). Ibrutinib and idelalisib were obtained from MedChem Express (Monmouth Junction, NJ, USA), and ABT-199 from Selleck Chemicals (Houston, TX, USA). BCL2 levels were determined by immunoblotting (Abcam, Cambridge, MA, USA). For survival assessment, WM cells underwent immunoblotting for cleaved PARP and caspase-3

(Abcam), and Annexin V staining (R&D Systems, Minneapolis, MN, USA) by flow cytometry. Synergistic drug interactions were determined by the Caspase-Glo<sup>®</sup> 3/7 assay (Promega, Madison WI, USA) in the presence of CXCL12 (50 nmol/l).

*CXCR4*<sup>WT</sup> and *CXCR4*<sup>S338X</sup> BCWM.1 and MWCL-1 cells expressed BCL2 protein, with higher levels observed in the latter. BCL2 levels were not impacted by *CXCR4* mutation status, or CXCL12 stimulation (Fig 1A). Treatment of *CXCR4*<sup>WT</sup> and *CXCR4*<sup>S338X</sup> BCWM.1 and MWCL-1 cells with ibrutinib or idelalisib induced caspase-3 and PARP cleavage at 6 h (Fig 1B), though modest Annexin V staining, denoting full apoptotic progression, was observed at 18 and 40 h (data not shown). CXCL12 abrogated ibrutinib- or idelalisib-related PARP and/or caspase-3 cleavage, and was more pronounced in *CXCR4*<sup>S338X</sup> WM cells. Similarly, ABT-199 induced PARP and caspase-3 cleavage in *CXCR4*<sup>S338X</sup> and *CXCR4*<sup>WT</sup> BCWM.1 and MWCL-1 cells. PARP and caspase-3 cleavage was less pronounced in MWCL-1 cells regardless of *CXCR4* mutation status, and probably reflected higher BCL2 protein levels (Fig 1A). CXCL12 also abrogated PARP and caspase-3 cleavage in ABT-199 treated *CXCR4*<sup>S338X</sup> BCWM.1 and MWCL-1 cells despite unaltered BCL2 protein levels (Fig 1A, C).

ABT-199 augmented PARP and caspase-3 cleavage in *CXCR4*<sup>S338X</sup> and *CXCR4*<sup>WT</sup> BCWM.1 and MWCL-1 WM cells treated with ibrutinib or idelalisib (Fig 1B), and led to increased Annexin V staining (Fig 1D). CXCL12 abrogated PARP and/or caspase-3 cleavage (Fig 1B), and Annexin V staining (data not shown) more so in *CXCR4*<sup>S338X</sup> following ABT-199 treatment with either ibrutinib or idelalisib. Addition of the *CXCR4* antagonist AMD3100 abrogated CXCL12 protective effects, and augmented PARP and caspase-3 cleavage (Fig 1B), and Annexin V staining (data not shown) in *CXCR4*<sup>S338X</sup> cells treated with ABT-199 alone and with ibrutinib or idelalisib.

To further delineate the impact of ABT-199 on ibrutinib- or idelalisib-related treatment effects, we used a caspase-3/7 cleavage assay to assess for drug synergy. Synergistic interactions (combination index >1.0) were evident at nearly all dose combinations of ABT-199 with either ibrutinib or idelalisib in *CXCR4*<sup>WT</sup> BCWM.1 and MWCL-1 cells in the




Fig 1. Apoptotic changes related to ABT-199 alone, and in combination with ibrutinib or idelalisib in CXCR4<sup>WT</sup>- and CXCR4<sup>S338X</sup>-engineered WM cells. (A) Protein levels of BCL2 following CXCL12 in vector only, CXCR4<sup>WT</sup> and CXCR4<sup>S338X</sup> BCWM.1 and MWCL-1 cells; (B) Caspase-3 and PARP cleavage following ibrutinib (IB), idelalisib (ID), ABT-199 (ABT), in the presence or absence of CXCL12 (SDF) and AMD3100 (AMD); (C) Caspase-3 and PARP cleavage in CXCR4<sup>S338X</sup> BCWM.1 and MWCL-1 cells treated with ABT-199 in the absence or presence of CXCL12 and AMD3100 (AMD); (D) CXCR4<sup>WT</sup> and CXCR4<sup>S338X</sup> expressing WM cells were treated for 18 h with vehicle control (dimethylsulphoxide; DMSO), ibrutinib (IB) or ABT-199 (ABT) alone and in combination in the presence of CXCL12. Annexin V staining was performed to assess apoptosis. Results from a representative study set of are shown. Similar results were obtained with idelalisib.

presence of CXCL12. Synergistic interactions were also evident, though at higher dose combinations of ABT-199, with either ibrutinib or idelalisib in CXCR4<sup>S338X</sup> WM cells,

reflecting the protective effects of CXCL12 in CXCR4<sup>WHIM</sup>-mutated cells (Fig 2A, B). The impact of ABT-199 on ibrutinib- or idelalisib-related treatment effect was also assessed in




Fig 2. Treatment effects of ABT-199 in combination with ibrutinib or idelalisib in  $CXCR4^{WT}$  and  $CXCR4^{S338X}$  expressing cell lines and primary WM patient cells. Synergistic drug interactions for ABT-199 with either ibrutinib or idelalisib in  $CXCR4^{WT}$  and  $CXCR4^{S338X}$  expressing BCWM.1 (A) and MWCL-1 (B) cells were determined in triplicate sample sets in the presence of CXCL12 (50 nM) 6 h following treatment at indicated doses using a caspase-3/7 cleavage assay. Combination Index  $>1.0$  denotes synergistic interactions. Apoptotic changes following ABT-199 alone, and in combination with ibrutinib or idelalisib in primary WM cells genotyped for MYD88 and CXCR4 mutations. Results from flow cytometric studies of *ex vivo* treated WM cells (CD19<sup>+</sup> gated) from (C) untreated WM patients ( $n = 4$ ) or (D) WM patients on active ibrutinib treatment ( $n = 3$ ). Cells were treated with vehicle control (DMSO), ibrutinib (IB), idelalisib (ID) and ABT-199 (ABT), alone and in combination.  $P = 0.02$  in untreated WM patient cells comparing any *ex vivo* treatment versus vehicle control;  $P \leq 0.05$  for ABT-199 combinations versus any monotherapy in untreated WM patient cells;  $P = 0.04$  for ABT-199 versus vehicle control for cells taken from patients on active ibrutinib therapy. All patients expressed MYD88<sup>L265P</sup>. Patients WM1, WM2, WM5, and WM6 expressed  $CXCR4^{S338X}$  mutations.

bone marrow (CD19-sorted) WM cells from 4 (2 MYD88<sup>L265P</sup>  $CXCR4^{WT}$ ; 2 MYD88<sup>L265P</sup>  $CXCR4^{S338X}$ ) untreated WM patients within their microenvironment. *Ex vivo* treatment of these cells with ABT-199 resulted in both direct ( $P = 0.02$ ) and enhanced apoptosis when combined with either ibrutinib or idelalisib ( $P \leq 0.05$  vs. any monotherapy) regardless of  $CXCR4$  mutation status (Fig 2A). We also examined ABT-199 in primary WM cells within their microenvironment from three patients (1 MYD88<sup>L265P</sup>  $CXCR4^{WT}$ ; 2 MYD88<sup>L265P</sup>  $CXCR4^{S338X}$ ) on active ibrutinib treatment for  $\geq 6$  months (Fig 2C). While *ex vivo* ibrutinib treatment had little effect, treatment with ABT-199 induced apoptosis in WM cells from two of three patients (Fig 2D).

In these studies, we sought to clarify if BCL2 expression was impacted by  $CXCR4^{WHIM}$  mutations, and whether BCL2 contributed to ibrutinib and idelalisib resistance in

$CXCR4^{WHIM}$ -mutated WM cells. Despite the lack of BCL2 modulation by CXCL12, BCL2 protected against ibrutinib- and idelalisib-triggered apoptosis in  $CXCR4^{WT}$  and  $CXCR4^{S338X}$  BCWM.1 and MWCL-1 cells. ABT-199 triggered apoptosis in WM cells regardless of  $CXCR4^{WHIM}$  mutation status and prior ibrutinib exposure. However, more robust CXCL12 protection against ABT-199 was observed in  $CXCR4^{S338X}$ -mutated cells, a finding that could be related to AKT1 and MAPK1 hyper-activation (Cao *et al*, 2014). AMD3100 blocked the protective effects of CXCL12 in WM cells treated with ABT-199 alone, and with ibrutinib or idelalisib. The long-term safety and efficacy of AMD3100 administration was recently demonstrated in WHIM-syndrome patients, and provides a paradigm for CXCR4 inhibition in WM patients.

Our findings therefore show that ABT-199 induces direct apoptosis, and enhances ibrutinib and idelalisib triggered

apoptosis in both CXCR4<sup>WT</sup> and CXCR4<sup>WHIM</sup> WM cells. These findings may be relevant to other therapeutics, and support further investigation of ABT-199 alone, and in combination strategies in WM patients.

## Acknowledgements

The authors acknowledge the generous support of the Leukemia and Lymphoma Society for a Translational Research Grant, Peter S. Bing M.D., the Edward and Linda Nelson Fund for WM Research, the Kerry Robertson Fund for WM Studies, in support of these studies.

## Authorship contributions

YC, GY and SPT conceived and designed the experiments. SPT, GY, ZRH performed the data analysis. JC, XL, LX, YC, GY, EH, and NT performed the laboratory experiments. SK, JJC, MSD, and SPT participated in patient care, sample and data collection. SPT wrote the manuscript.

## Disclosure of conflicts of interest

SPT received research funding, speaking honoraria and/or consulting fees from Pharmacyclics Inc., Janssen Pharmaceuticals Inc., and Gilead Pharmaceuticals, Inc. MSD received research funding from Pharmacyclics, Inc., consulting fees

from Janssen Pharmaceuticals, Inc., Gilead Pharmaceuticals, Genentech, and Infinity Pharmaceuticals.

Yang Cao<sup>1,2\*</sup>

Guang Yang<sup>1,2\*</sup>

Zachary R. Hunter<sup>1,3,4</sup>

Xia Liu<sup>1,2</sup>

Lian Xu<sup>1</sup>

Jie Chen<sup>1</sup>

Nickolas Tsakmaklis<sup>1</sup>

Evdoxia Hatjiharissi<sup>3,4</sup>

Sandra Kanan<sup>1</sup>

Matthew S. Davids<sup>1,2</sup>

Jorge J. Castillo<sup>1,2</sup>

Steven P. Treon<sup>1,2</sup>

<sup>1</sup>Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, <sup>2</sup>Department of Medicine, Harvard Medical School, <sup>3</sup>Department of Pathology, Boston University Medical Center, Boston, MA, USA, and <sup>4</sup>Theagenio Cancer Hospital, Thessaloniki, Greece  
E-mail: steven\_treon@dfci.harvard.edu

\*Co-first authors.

**Keywords:** Waldenström macroglobulinemia, CXCR4, BCL2, Ibrutinib, ABT-199

## References

- Cao, Y., Hunter, Z.R., Liu, X., Xu, L., Yang, G., Chen, J., Patterson, C.J., Tsakmaklis, N., Kanan Rodig, S., Castillo, J.J. & Treon, S.P. (2014) The WHIM-like CXCR4<sup>S338X</sup> somatic mutation activates AKT1 and MAPK1, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenström's Macroglobulinemia. *Leukemia*, doi: 10.1038/leu.2014.187 [Epub ahead of print].
- Chng, W.J., Schop, R.F., Price-Troska, T., Ghobrial, I., Kay, N., Jelinek, D.F., Gertz, M.A., Dispenzieri, A., Lacy, M., Kyle, R.A., Greipp, P.R., Tschumper, R.C., Fonseca, R. & Bergsagel, P.L. (2006) Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. *Blood*, **108**, 2755–2763.
- Davids, M.S., Seymour, J.F., Gerecitano, J.F., Kahl, B.S., Pagel, J.M., Wierda, W.G., Anderson, M.A., Rudersdorf, N., Gressick, L.A., Montalvo, N.P., Yang, J., Zhu, M., Dunbar, M., Cerri, E., Enschede, S.H., Humerickhouse, R. & Roberts, A.W. (2014) Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. *Journal of Clinical Oncology*, **32** (Suppl. 5), Abstract 8522.
- Gopal, A.K., Kahl, B.S., de Vos, S., Wagner-Johnston, N.D., Schuster, S.J., Jurczak, W.J., Flinn, I.W., Flowers, C.R., Martin, P., Viardot, A., Blum, K.A., Goy, A.H., Davies, A.J., Zinzani, P.L., Dreyling, M., Johnson, D., Miller, L.L., Holes, L., Li, D., Dansey, R.D., Godfrey, W.R. & Salles, G.A. (2014) PI3K $\delta$  inhibition by idelalisib in patients with relapsed indolent lymphoma. *New England Journal of Medicine*, **370**, 1008–1018.
- Hunter, Z.R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R.J., Tripsas, C., Patterson, C.J., Sheehy, P. & Treon, S.P. (2014) The genomic landscape of Waldenström's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. *Blood*, **123**, 1637–1646.
- Roccaro, A.M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Sahin, I., Kuhne, M., Cardarelli, P., Cohen, L., San Miguel, J.F., Garcia-Sanz, R. & Ghobrial, I.M. (2014) A novel activating mutation of CXCR4 plays a crucial role in Waldenström Macroglobulinemia biology. *Blood*, **123**, 4120–4131.
- Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R.J., Patterson, C.J., Tripsas, C., Arcaini, L., Pinkus, G.S., Rodig, S.J., Sohani, A.R., Harris, N.L., Laramie, J.M., Skifter, D.A., Lincoln, S.E. & Hunter, Z.R. (2012) MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. *New England Journal of Medicine*, **367**, 826–833.
- Treon, S.P., Tripsas, C., Yang, G., Cao, Y., Xu, L., Hunter, Z.R., Cropper, S.J., Mostyn, P., Meid, K., Warren, D., Patterson, C.J., Varma, G., Laubach, J.P., Paba-Prada, C.E., Kunsman, J., Ghobrial, I.M., Kanan, S., Advani, R.H. & Palomba, M.L. (2013) A Prospective Multicenter Study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in patients with relapsed or Refractory Waldenström's Macroglobulinemia. *Blood*, **122**, Abstract 251.
- Yang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R.J., Patterson, C.J., Buhrlage, S.J., Gray, N., Tai, Y.T., Anderson, K.C., Hunter, Z.R. & Treon, S.P. (2013a) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. *Blood*, **122**, 1222–1232.
- Yang, G., Liu, X., Zhou, Y., Xu, L., Cao, Y., Manning, R.M., Patterson, C.J., Tripsas, C.K., Hunter, Z.R., Buhrlage, S., Gray, N.S. & Treon, S.P. (2013b) PI3K/AKT1 pathway is activated by MYD88 L265P and use of PI3K-Delta inhibitors induces robust tumor cell killing in Waldenström's Macroglobulinemia. *Blood (ASH Annual Meeting abstracts)*, **122**, 4255.